Skip to main content
GutCited

Açıklama

Fecal metabolomics profiling highlights key metabolites significantly altered in Crohn's disease patients with intestinal fibrosis compared to those without fibrotic complications.

Figure 3

Chart

Source Paper

Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease.

EMBO molecular medicine (2024)

PMID: 39271960

DOI: 10.1038/s44321-024-00129-8

Cite This Figure

![Figure 3: Fecal metabolomics profiling highlights key metabolites significantly altered in Crohn's disease patients with intestinal fibrosis compared to those without fibrotic complications.]()

> Source: Xuehua Li et al. "Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in." *EMBO molecular medicine*, 2024. PMID: [39271960](https://pubmed.ncbi.nlm.nih.gov/39271960/)
<figure>
  <img src="" alt="Fecal metabolomics profiling highlights key metabolites significantly altered in Crohn's disease patients with intestinal fibrosis compared to those without fibrotic complications." />
  <figcaption>Figure 3. Fecal metabolomics profiling highlights key metabolites significantly altered in Crohn's disease patients with intestinal fibrosis compared to those without fibrotic complications.<br>  Source: Xuehua Li et al. "Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in." <em>EMBO molecular medicine</em>, 2024. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39271960/">39271960</a></figcaption>
</figure>

İlgili Kanıtlar

C
L-Glutamine için Crohn's Disease

Derece C · 3 çalışma